BioAffinity Stock Based Compensation To Revenue from 2010 to 2024
| BIAF Stock | USD 1.25 0.01 0.81% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.29568541 | Current Value 0.28 | Quarterly Volatility 18.11046441 |
Check BioAffinity Technologies, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies, Valuation or Volatility modules.
BioAffinity | Stock Based Compensation To Revenue |
Currently Active Assets on Macroaxis
When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:Check out the analysis of BioAffinity Technologies, Correlation against competitors. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.